Scarica l'app Stockscreener
3.99
2.31%
0.09
Precedente Chiudi:
$3.90
Aprire:
$3.9
Volume 24 ore:
216.70K
Relative Volume:
0.75
Capitalizzazione di mercato:
$161.58M
Reddito:
-
Utile/perdita netta:
$-58.75M
Rapporto P/E:
-0.9221
EPS:
-4.327
Flusso di cassa netto:
$-50.79M
1 W Prestazione:
-3.62%
1M Prestazione:
-5.45%
6M Prestazione:
+64.88%
1 anno Prestazione:
+49.44%
Intervallo 1D:
$3.83
$4.13
Intervallo di 1 settimana:
$3.83
$4.1708
Portata 52W:
$2.23
$5.38
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Nome
Onkure Therapeutics Inc
Settore
Industria
Telefono
(720) 307-2892
Indirizzo
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Compare OKUR vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
3.99 | 159.15M | 0 | -58.75M | -50.79M | -4.327 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-30 | Iniziato | Evercore ISI | Outperform |
| 2024-12-05 | Iniziato | Leerink Partners | Outperform |
| 2024-10-10 | Iniziato | Oppenheimer | Outperform |
| 2023-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | Downgrade | Jefferies | Buy → Hold |
| 2023-12-15 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-12-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | Iniziato | William Blair | Outperform |
| 2023-08-28 | Iniziato | H.C. Wainwright | Buy |
| 2023-07-03 | Iniziato | BofA Securities | Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-01-27 | Iniziato | Robert W. Baird | Outperform |
| 2021-12-21 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-22 | Iniziato | Ladenburg Thalmann | Buy |
| 2021-05-04 | Iniziato | Jefferies | Buy |
| 2021-05-04 | Iniziato | Piper Sandler | Overweight |
| 2021-05-04 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Onkure Therapeutics Inc Borsa (OKUR) Ultime notizie
Prosight Management, LP Reduces OnKure Therapeutics (OKUR) Stake in Second Quarter - GuruFocus
Oppenheimer Adjusts OnKure Therapeutics PT to $14 From $30, Maintains Outperform Rating - marketscreener.com
OnKure Reprices Underwater Stock Options to Boost Retention - TipRanks
Onkure Therapeutics Inc (OKUR) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
LifeSci Capital Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Maintains Target Price $16 - Moomoo
OnKure Therapeutics has cash runway into 2029 - BizWest
JonesTrading Maintains OnKure Therapeutics(OKUR.US) With Hold Rating - Moomoo
OnKure Therapeutics reports Q2 2026 net loss $15.3M; $176.4M cash runway into 2029 - TradingView
OKUR: IND-enabling PI3Ka programs advance toward 2027 filings, backed by $176M cash runway into 2029 - TradingView
OnKure Therapeutics, Inc. Q2 2026: Net loss $(30.5M) for 6M, EPS $(0.31) — 10-Q Summary - TradingView
OnKure Therapeutics (Nasdaq: OKUR) raises $150M to fund PI3Kα drugs - Stock Titan
OKUR: Q2 2026 net loss was $15.3M; cash reserves strengthened by $150M private placement - TradingView
OnKure Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - Yahoo Finance
OnKure Therapeutics Rings the Closing Bell - Nasdaq
OnKure Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
OnKure Therapeutics, Inc. Revenue Breakdown – NASDAQ:OKUR - TradingView
Vivo Capital LLC Invests $7.98 Million in OnKure Therapeutics, Inc. $OKUR - MarketBeat
Onkure Therapeutics Inc (OKUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Onkure Therapeutics Inc (OKUR) Balance Sheet - TradingKey
Onkure Therapeutics Inc (OKUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OKUR|Onkure Therapeutics Inc|Price:4.050|Chg%:-0.070 - TradingKey
Onkure Therapeutics Inc (OKUR) Financial Health: Profitability & Balance Sheet Analysis - tradingkey.com
OnKure Therapeutics (OKUR) Slips 1.7% as Shares Test Key Support ZoneNAAIM Leverage - dars.gov.et
Onkure Therapeutics Inc (OKUR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Onkure Therapeutics Inc (OKUR) Institutional Confidence - TradingKey
Onkure Therapeutics Inc (OKUR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Onkure Therapeutics Inc (OKUR) Cash Flow - TradingKey
Onkure Therapeutics Inc (OKUR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Onkure Therapeutics Inc (OKUR) Income Statement - tradingkey.com
OKUR Options Volatility — NASDAQ:OKUR - TradingView
OKUR Options Chain — NASDAQ:OKUR - TradingView
Price to earnings forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
Price to sales forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
H.C. Wainwright cuts OnKure stock price target to $21 on valuation changes - Investing.com
OKUR Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
OnKure Therapeutics Price Target Cut to $21.00/Share From $27.00 by HC Wainwright & Co. - Moomoo
H.C. Wainwright Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Cuts Target Price to $21 - Moomoo
OnKure Therapeutics Inc. (OKUR) Q1 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineEarnings Miss Streak - dars.gov.et
OnKure Therapeutics (OKUR) Declines 2.7% as Shares Test Key Support ZoneRip Sell Trade - dars.gov.et
Enterprise value to revenue forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
OnKure Therapeutics Spotlights Allosteric PI3Kα Drugs as 2027 IND Targets Near - Yahoo Finance
We're Not Very Worried About OnKure Therapeutics' (NASDAQ:OKUR) Cash Burn Rate - Sahm
Price to book forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
ETFs Investing in OnKure Therapeutics, Inc. Class A Stocks - TradingView
Enterprise value to EBITDA forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026 - The Manila Times
OnKure lines up July 15 virtual event on cancer-drug design - Stock Titan
OnKure Therapeutics to host virtual event on Ju... - Pluang
OnKure Therapeutics (OKUR) Slips 2% as Stock Tests Support Near $4.24Factor ETF Flow - dars.gov.et
OnKure Therapeutics, Inc.(NasdaqGM: OKUR) added to Russell 2000 Index - marketscreener.com
Onkure Therapeutics Inc Azioni (OKUR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):